Local research. Human connections. WCR Miami Lakes (786) 483-7856
Back to study searchNCT07929402
Not yet recruitingNCT07929402ClinicalTrials.gov record

Magnesium-Enhanced ESPB for Respiratory Recovery and Analgesia in Unilateral Rib Fractures

Unilateral Rib Fracture · ESPB · MgSO4 · Respiratory Recovery · Analgesic Efficacy

THE QUICK READ

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type
Interventional
Phase
Not applicable
Age range
18 years - 60 years
Sex eligible
All sexes
Healthy volunteers
Not accepted
Participants
36 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

Chest wall trauma is a major cause of morbidity among trauma patients. Rib fractures are associated with severe pain, impaired ventilation, reduced cough efficiency, secretion retention, prolonged hospital stay, and increased mortality. Rib fractures are also associated with concomitant thoracic injuries, head, extremity, abdominal, and blunt cardiac injuries.

These patients have poor overall clinical outcomes and are at increased risk for multiple complications.

Thoracic complications of rib fractures are common, including pneumonia, pulmonary effusion, aspiration, acute respiratory distress syndrome (ARDS), pulmonary emboli, and atelectasis or lobar collapse.

these complications are important as targeted interventions may enable risk reductions. Effective analgesia is therefore a cornerstone in the management of chest trauma.

Systemic opioids have traditionally been used for pain management; however, their use is associated with respiratory depression, sedation, nausea, vomiting, and impaired pulmonary rehabilitation. Regional anesthesia techniques have emerged as valuable alternatives that provide effective analgesia while minimizing opioid-related adverse effects.

The ultrasound-guided erector spinae plane block (ESPB), first described by Forero, is a fascial plane block in which local anesthetic is deposited deep to the erector spinae muscle adjacent to the transverse process. ESPB has demonstrated efficacy in thoracic surgery, breast surgery, and rib fracture analgesia, improving pain scores and respiratory mechanics.

Magnesium sulfate (MgSO₄) possesses antinociceptive properties through antagonism of N-methyl-D-aspartate (NMDA) receptors and modulation of calcium influx. As an adjuvant to local anesthetics, magnesium sulfate has been shown to prolong analgesia and reduce opioid requirements in various regional anesthesia techniques. Recent ESPB studies and systematic reviews have suggested improved analgesic efficacy when magnesium sulfate is added to local anesthetics.

However, there is currently limited evidence regarding the role of magnesium sulfate as an adjuvant to ESPB specifically in patients with unilateral rib fractures. Therefore, this study aims to investigate whether adding magnesium sulfate to bupivacaine in ESPB improves analgesic outcomes and respiratory recovery in this patient population.

Read the full description

Aim of the Study To evaluate the effect of adding magnesium sulfate to bupivacaine in ultrasound-guided erector spinae plane block on analgesic efficacy and respiratory recovery in patients with unilateral rib fractures.

Research Methods and Techniques Study Design: Prospective, randomized, comparative, double-blind controlled clinical trial.

Operative Suite: This study will be conducted in the Trauma Unit located in Trauma Hospital - Assiut University.

Study duration: From September 2026 until completion of patient recruitment. All participants will sign an informed consent before inclusion in the study after being individually informed.

Patient Enrollment and sample size:

Sample Size calculation Sample size was calculated using G\*power, version 3.1.9.2. Based on earlier studies, we expected to find significant difference in total postoperative morphine consumption (mg) in control group and Magnesium sulphate group (effect size = 0.80) (El Sherif et al., 2022). With a power of 80% (using independent t-test and α\*= 0.05) the sample needed for the study was estimated to be 42 patients (21 per each group). Considering an anticipated drop-out rate of 15%, a final sample size of 25 patients per group (50 patients in total) will be enrolled

.

Patients will be randomly allocated in a 1:1 ratio using a computer-generated randomization sequence. Allocation concealment will be achieved using sequentially numbered opaque sealed envelopes. The study solution will be prepared by an anesthesiologist not involved in:

Block performance. Data collection. Statistical analysis.

Patients, outcome assessors, and treating physicians will remain blinded to group allocation.

Group C (Control Group) Patients in Group C will receive: Bupivacaine 0.25% 20 mL Plus 5 mL normal saline total volume = 25 mL Group M (Magnesium sulfate Group) Patients in Group M will receive: Bupivacaine 0.25% 20 mL Plus Magnesium sulfate 500 mg (5 mL) Total volume adjusted to 25 mL.

Justification of Dose The magnesium sulfate dose of 500 mg was selected based on randomized ESPB studies and recent systematic reviews demonstrating improved analgesia with acceptable safety profiles using doses between 250 and 500 mg7.

Study Protocol

The ESPB protocol will be standardized.

Pre-Block Assessment

All patients will undergo:

Detailed history. Clinical examination. Chest imaging review. Baseline VAS score. Baseline respiratory assessment. Baseline vital signs. Monitoring Standard monitoring: ECG, non-invasive mean arterial blood pressure (MAP), pulse oximetry, and respiratory rate 2.

Intravenous access will be secured. Technical Procedure (Intervention)

ESPB Technique: The block will be performed by an experienced anesthesiologist under strict aseptic precautions.

Positioning: Sitting, lateral decubitus, or prone position based on patient tolerance.

Target Level: Mid-thoracic level corresponding to the center of the fractured ribs (typically T4-T5).

Ultrasound Technique:

A high-frequency linear ultrasound transducer will be placed in a longitudinal paramedian orientation approximately 3 cm lateral to the T5 spinous process on the affected side.

The following structures will be identified:

Trapezius muscle. Rhomboid major muscle. Erector spinae muscle. T5 transverse process Local Anesthesia: the needle insertion site will be infiltrated with 1-2 mL of 1% lidocaine in both groups to facilitate needle insertion and minimize procedural discomfort. The same volume and concentration will be used for all patients.

Needle Insertion: A 22-gauge 80-100 mm block needle will be inserted using an in-plane approach, cranio-caudal or caudo-cranial direction. Advance until the needle tip hits the transverse process .

After negative aspiration:

2 mL saline hydrodissection will confirm correct needle placement. The study solution will then be injected deep into the erector spinae muscle. Adequate linear spread beneath the erector spinae muscle will be confirmed by US.

Thirty minutes after the procedure, a pinprick assessment will be performed to confirm the sensory distribution of the block.

Ultrasonographic assessment of diaphragmatic excursion Patients will undergo ultrasonographic assessment of ipsilateral diaphragmatic excursion before performing the block and at predetermined postoperative intervals.

A low-frequency curved-array ultrasound transducer (approximately 2-5 MHz) will be placed in the subcostal region at the mid-clavicular line with the ultrasound beam directed perpendicular to the posterior third of the ipsilateral hemidiaphragm.

M-mode ultrasonography will be used to record diaphragmatic displacement during deep inspiration.

Patients will be instructed to perform maximal deep inspiration following normal expiration.

Three consecutive respiratory cycles will be recorded, and the mean of three measurements will be used as the diaphragmatic excursion value at each assessment point.

Incentive spirometry Volumetric incentive spirometry (VIS) is a simple, non-invasive respiratory device.

It provides a direct measurement of inspired volume, allowing objective assessment of inspiratory capacity.

IT is used to encourage slow, deep inspiration and promote lung expansion

Analgesic Regimen Patients will receive rescue analgesia if VAS ≥ 4: IV Morphine 0.05 mg/kg (time of first dose).

Total morphine consumption will be recorded during the first 24 hours.

Data collection Demographic Data Age, Sex, Weight, Height, and BMI ASA status.

Trauma Characteristics Number of fractured ribs Type and timing of the trauma Side of injury Presence of pulmonary contusion.

Hemodynamic Variables Recorded at:

Time: Baseline, 30 min, 2 h, 4 h, 6 h, 12 h, 24 h, and at the time of rescue analgesia.

Including:

Heart rate Mean arterial pressure Respiratory rate SpO₂ Pain Assessment

VAS score:

Baseline, 30 min, 2 h, 4 h, 6 h, 12 h, 24 h, and at the time of rescue analgesia.

At:

Rest. Coughing. Visual Analog Scale \[VAS\] scores 8 Pain Level Score No pain 0 Mild pain 1-3 Moderate pain 4-6 Severe pain 7-10

Respiratory Assessment Respiratory rate Ipsilateral diaphragmatic excursion will be recorded at Baseline, 30 min, 2 h, 4 h, 6 h, 12 h, 24 h, and at the time of rescue analgesia, assessed in the same position and by blinded assessor.

ΔDE=DEt -DE at baseline AUCΔDE,0-24h Incentive spirometry volume will be recorded at Baseline, 30 min, 2 h, 4 h, 6 h, 12 h, 24 h, and at the time of rescue analgesia, assessed in the same position and by blinded assessor.

Effective cough score. Pulmonary complications.

Semiquantitative Cough Strength Score (SCSS)9 Cough Strength Score No cough on command 0 Audible movement of air but no audible cough 1 Weakly (barely) audible cough 2 Clearly audible cough 3 Strong cough 4 Multiple sequential strong coughs 5

Analgesic Assessment VAS pain scores at rest and during exertion at predefined intervals over the first 24 hours post-block.

Time to first request for rescue analgesia (administered according to institutional pain management protocols if pain scores exceed specific thresholds).

Total cumulative dose of rescue analgesia consumed during the study period. Patient satisfaction score. Number of morphine boluses. Patient Satisfaction Score10 Description Score Very dissatisfied

1 Dissatisfied 2 Neutral 3 Satisfied 4 Very satisfied 5

Statistical Analysis Statistical analysis was performed using SPSS (Statistical Package for the Social Sciences), version 20 (IBM Corp., Armonk, NY, USA). Data normality was assessed using the Shapiro-Wilk test. Quantitative variables were expressed as mean ± standard deviation (SD). Serial measurements (VAS score, heart rate, mean arterial pressure, respiratory rate, and SpO₂) were analyzed using repeated-measures analysis of variance (ANOVA), followed by appropriate post hoc testing when indicated. Categorical variables were presented as frequency (n) and percentage (%) and compared using the Chi-square test. A two-sided P value \< 0.05 was considered statistically significant.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

Age 18-65 years. ASA physical status I-II. Patients with 2-5 unilateral rib fractures confirmed radiologically. Stable hemodynamics

Exclusion Criteria:

Patient refusal. Bilateral rib fractures or flail chest. Severe head, abdominal, or spinal injury Contraindications to regional anesthesia (coagulopathy, local infection). Known allergies to amide local anesthetics or magnesium sulfate. Severe traumatic brain injury. Heart block or severe hepatic or renal impairment.

Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment
Random assignment
Masking
Quadruple masked
Control Group - Bupivacaine Alone

Participants will receive ultrasound-guided erector spinae plane block using 20 mL of bupivacaine 0.25% combined with 5 mL of normal saline, giving a total injection volume of 25 mL.

Drug: Bupivacaine 0.25%

Magnesium Sulfate Group - Bupivacaine Plus Magnesium

Participants will receive ultrasound-guided erector spinae plane block using 20 mL of bupivacaine 0.25% combined with magnesium sulfate 500 mg in 5 mL, giving a total injection volume of 25 mL.

Drug: Bupivacaine 0.25% · Drug: Magnesium sulfate 500 mg

Bupivacaine 0.25% DRUG

20 mL of bupivacaine 0.25% will be combined with 5 mL of normal saline (total volume 25 mL) and administered through ultrasound-guided erector spinae plane block.

Magnesium sulfate 500 mg DRUG

Magnesium sulfate 500 mg (5 mL) will be combined with 20 mL of bupivacaine 0.25% (total volume 25 mL) and administered through ultrasound-guided erector spinae plane block.

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Diaphragmatic excursion

Time frame: 24 hours

To compare the area under the curve of the change in ipsilateral diaphragmatic excursion from baseline over the first 24 hours after ultrasound-guided ESPB.

Diaphragmatic excursion will be measured in centimeters .

Secondary measures

Incentive spirometry

Time frame: 24 hour

volume will be assessed in the same position and by blinded assessor in milliliters

Semiquantitative Cough Strength Score (SCSS)

Time frame: 24 hours

No cough on command 0 Audible movement of air but no audible cough 1 Weakly (barely) audible cough 2 Clearly audible cough 3 Strong cough 4 Multiple sequential strong coughs 5

Higher means better

Visual Analog Scale [VAS] scores

Time frame: 24hours

at rest and during exertion No pain 0 Mild pain 1-3 Moderate pain 4-6 Severe pain 7-10 Higher means worse

Time to first request for rescue analgesia

Time frame: 24 hours

administered according to institutional pain management protocols if pain scores exceed specific thresholds will be measured in hours after the block

Total cumulative dose of rescue analgesia

Time frame: 24 hours

administered according to institutional pain management protocols if pain scores exceed specific thresholds will be measured in milligrams.

Number of rescue analgesia boluses

Time frame: 24 hours

administered according to institutional pain management protocols if pain scores exceed specific thresholds will be measured in milligrams.

Patient satisfaction score

Time frame: 24 hours

Very dissatisfied 1 Dissatisfied 2 Neutral 3 Satisfied 4 Very satisfied 5 Higher means better

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (0)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

No locations are listed. Use the official study contact.

Study team and timeline

Lead sponsor
Assiut University
Study start
Nov 30, 2026 Estimated
Primary completion
Oct 1, 2027 Estimated
Study completion
Oct 1, 2028 Estimated
First posted
Nov 10, 2026 Actual
Last updated
Nov 10, 2026 Actual

Official study contacts

mohammed N Fouly, MBBChCONTACTMohamed.foly@med.aun.edu.eg+201555982840
Official study title

Effect of Magnesium Sulfate as an Adjuvant to Ultrasound-Guided Erector Spinae Plane Block on Respiratory Recovery and Analgesic Efficacy in Patients With Unilateral Rib Fractures: A Prospective, Randomized, Comparative, Double-Blind, Controlled Clinical Trial.

A HUMAN NEXT STEP

Ask Wellness Clinical Research

Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.

Please do not include medical records, diagnoses, medications, insurance numbers or other sensitive details. This form is for general questions, not urgent care.

Sending a question does not enroll you in a trial.

Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.

Retrieved: Nov 11, 2026 · Last registry update: Nov 10, 2026